Hazar, VolkanKarasu, Gulsun TezcanUygun, VedatOzbek, NamikKarakukcu, MusaOzturk, GulyuzOk Bozkaya, Ikbal2020-12-012020-12-0120201042-81941029-2403https://doi.org/10.1080/10428194.2020.1716220https://hdl.handle.net/11454/62709We examined outcomes of 51 pediatric patients with relapsed acute leukemia (AL) who underwent a second allogeneic hematopoietic stem cell transplantation (alloHSCT). After a median follow-up of 941 days (range, 69-2842 days), leukemia-free survival (LFS) and overall survival (OS) at 3 years were 26.6% and 25.6%, respectively. the nonrelapse mortality rate (NMR) and cumulative incidence of relapse (CIR) were 36.4% and 42.4%, respectively. the Cox regression analysis demonstrated that the risk factors at second transplantation for predicting limited LFS were active disease (hazard ratio (HR) = 5.1), reduced intensity conditioning (RIC) (HR = 5.0), matched unrelated donor (MUD) (HR = 3.4) and performance score <80 (HR = 3.2). Pediatric patients with AL who relapsed after their first alloHSCT may survive with a second alloHSCT. Disease status, conditioning intensity, donor type, and performance score at the second transplantation are the relevant risk factors. A score based on these factors may predict the results of the second transplantation.en10.1080/10428194.2020.1716220info:eu-repo/semantics/closedAccessPosttransplantation relapsesecond transplantationacute leukemiachildrenArticle61614651474WOS:0005133015000012-s2.0-8507944352632037917Q2Q3